Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 7/20 | 0.59 |
| ▸ | MAOA | P21397 | 6/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | SDHA | P31040 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1394542 | 1.00 | CALML3 (0.59) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL1394014 | 0.93 | CALML3 (0.60) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL10196494 | 0.90 | MAOA (0.57) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL3176660 | 0.90 | MAOA (0.57) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL1393860 | 0.90 | MAOA (0.57) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL1393525 | 0.89 | CALML3 (0.60) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL6302777 | 0.89 | CALML3 (0.74) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL6302773 | 0.89 | CALML3 (0.74) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL10197503 | 0.88 | CALML3 (0.62) | CALML3MAOAMAOBCYP3A4CYP2C19 | |
| SCHEMBL1394066 | 0.88 | CALML3 (0.62) | CALML3MAOAMAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660465-B1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES | MELINTA THERAPEUTICS INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8895741-B2 | Process for the synthesis of biaryl oxazolidinones | MELINTA THERAPEUTICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130066076-A1 | Process for the Synthesis of Biaryl Oxazolidinones | MELINTA SUBSIDIARY CORP. | 2013-03-14 | — | — | US | disclosed |
| US-8324398-B2 | Process for the synthesis of biaryl oxazolidinones | RIB-X PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100022772-A1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDNONES | RIB-X PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| EP-1660465-A2 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES | Rib-X Pharmaceuticals, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005012271-A2 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES | RIB-X PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066076-A1 | Process for the Synthesis of Biaryl Oxazolidinones | PCNA, PGC, SBDS | CALML3 4667/4885MAOA 1272/4885MAOB 1133/4885 |
| US-20100022772-A1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDNONES | PCNA, PGC, MKI67 | CALML3 4706/4885MAOA 824/4885MAOB 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.